Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ESC HF 25: CRISPR in ATTR-CM: Hereditary vs Wild-Type
Author(s): Marianna Fontana Added: 8 months ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,… View more

Heart Failure
Importance of Testing for CKD Among Patients With Type 2 Diabetes
Author(s): Pam Taub , Nikolaus Marx Added: 1 year ago
RP-UN-CAR-GB-0166 / June 2024This programme features a compelling discussion between two distinguished experts, Prof Pam Taub (University of California, San Diego, US) and Prof Nikolaus Marx (University Hospital RWTH, Aachen, DE), chairperson responsible for the most recent ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes. Together, they delve into a critical… View more

Guidelines & Statements

Prevention & Chronic Conditions
Research Area(s) / Expertise: Job title: Associate Adjunct Professor in Cardiology
Dr Payal Kohli is an Associate Adjunct Professor in Cardiology Division, Department of Medicine at Duke University and at Johns Hopkins University, US. Dr Kohli earned her undergraduate degree from Massachusetts Institute of Technology (MIT) with a perfect GPA and her medical degree from Harvard Medical School, magna cum laude. She is Board-certified in Internal Medicine, Cardiology and… View more
ADA 25: MariTide Treatment for Obesity in Patients with or without T2D
Author(s): Harold Bays Added: 6 months ago
ADA 2025 - Once-monthly MariTide treatment demonstrates around 15% average weight reduction at 52 weeks in patients with obesity, with or without type 2 diabetes.We are joined by Dr Harold Bays (L-MARC Research Center, Louisville, US) to discuss a 52-week, placebo-controlled, phase 2 randomised study (NCT05669599) investigating the efficacy, safety and tolerability of different doses of once… View more

Cardiovascular Renal Metabolic
Transthyretin Cardiac Amyloidosis: A Right-atrial Variant
Author(s): Narra Lavanya , Abraham Oomman Added: 9 months ago

Imaging & Diagnostics

Heart Failure
EASD 23: Efinopegdutide in NAFLD & T2D patients
Author(s): Samuel S Engel Added: 2 years ago
EASD 2023 — In this short interview, Dr Samuel S Engel (Associate Vice President at Merck) discusses a study investigating the effectiveness and safety of efinopegdutide (MK-6024) in patients with nonalcoholic fatty liver disease and type 2 diabetes (NCT04944992).The phase IIa study randomized 145 participants (efinopegdutide, n = 72; semaglutide, n = 73). The majority (55.2%) of participants… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
ADA 25: Final Results of the CATALYST Trial
Author(s): Added: 6 months ago
ADA 2025 - Final results from the CATALYST trial show mifepristone significantly improved glucose control in patients with hypercortisolism and difficult-to-control diabetes.We are joined by Dr John Buse (University of North Carolina, Chapel Hill, US) to discuss phase 4 results from CATALYST (NCT05772169), a randomised, placebo-controlled, multi-center trial investigating the safety and efficacy… View more

Cardiovascular Renal Metabolic
Lifestyle Modification after PCI
Author(s): Nicholas Nguyen , Katherine C Michelis Added: 1 year ago

Prevention & Chronic Conditions
Secondary Prevention of Atherosclerotic Cardiovascular Disease
Author(s): Madelyn Hurwitz , Olayinka J Agboola , Abhishek Gami , et al Added: 8 months ago

Prevention & Chronic Conditions
Gender Disparities in PAD
Author(s): Andrea Martinez , Jingwen Huang , Arash Harzand Added: 1 year ago

Demographic

Prevention & Chronic Conditions